Table 1 Clinical features and treatment regimens of MM patients
1 | 2 | 3. MM | 4. Control |
|---|---|---|---|
Age, median (range) | 56 (28–81) | 53 (22–68) | |
Gender, n (%) | Female/Male | 90/110 (45/55) | 99/101 (50/50) |
Ig subtype, n (%) | IGG k | 61 (30.5) | |
IGG l | 30 (15) | ||
IGA k | 48 (24) | ||
IGA l | 27 (13.5) | ||
Light chain (k/l) | 34 (17/17) | ||
Stage (Durie-Salmon), n (%) | II/III | 53/117 (31/69) | |
A/B | 129/41 (76/24) | ||
ISS, n (%) | I | 51 (30.2) | |
II/III | 45/73 (26.6/43.2) | ||
ECOG, n (%) | > 1 | 28/169 (16.6) | |
Hemoglobin | g/dL (range) | 10.4 (5.9–15.8) | |
Leukocytes | /mm3 | 6785 (2760–18,500) | |
Thrombocytes | 103/mm3 | 172 (28–788) | |
CRP | mg/dL | 8.0 (2.1–342) | |
LDH | IU/L | 200 (93–1037) | |
β2-MG | mg/L | 5.0 (1.5–47) | |
Albumin | g/L | 3.5 (1.6–5.1) | |
Treatment, n (%) | VCD, ASCT, LD | ||
VCD ± LD | |||
OS, median, months (%) | 66 (71) | ||
PFS, median, months (%) | 43.8 (44) | ||
Mortality, n (%) | |||
Follow-up period, median, months (range) | 30 (4.8–155) |